Boston Scientific Announces Investment in Electrophysiology Mapping Company CordisCortexReach a final acquisition agreement (CortexLast year, it received a $90 million investment from Cordis-X.), Boston Scientific expects to complete the transaction in the first half of 2025."Cortex was founded to provide doctors with smarter and more precise solutions for atrial fibrillation patients. Joining Boston Scientific will allow us to further develop this technology, which we believe has the potential to transform atrial fibrillation treatment for patients around the world."---Duke Rohlen Cortex, Inc. CEO"We believe that the addition of Cortex technology complements our electrophysiology portfolio, offering differentiated cardiac mapping services for complex atrial fibrillation cases. OptiMap has already demonstrated its ability to assist physicians in designing targeted ablation strategies for complex cases, thereby improving procedural efficiency and outcomes for patients with challenging atrial arrhythmias. We look forward to advancing this technology and driving the generation of future clinical evidence, with the goal of making it accessible to physicians and patients worldwide in the coming years."---Nick Spadea-Anello, Global President of Boston Scientific ElectrophysiologyIn the new era of electrophysiology, PFA is gradually replacing traditional thermal ablation technologies. Although PFA can address the poor safety of traditional thermal ablation, it still has many shortcomings during ablation, with atrial fibrillation recurrence being the most significant factor affecting the effectiveness of PFA treatment. The main reason for atrial fibrillation recurrence is the inability to effectively determine during surgery whether abnormal tissue has been completely ablated. To thoroughly ablate these abnormal electrical tissues, three-dimensional mapping technology is required for identification. It can be said that only precise targeting of the lesion can truly unleash the power of PFA technology.Unfortunately, in the field of 3D mapping, Johnson & Johnson'sCarto 3It is the industry-recognized sole benchmark and also the three-dimensional mapping system with the highest market share, which forms the basis for Johnson & Johnson's long-term dominance in the electrophysiology field. In the traditional thermal ablation era, whether it was catheters or three-dimensional mapping systems, hardly any company could compete with Johnson & Johnson. Now, in the PFA era, companies like Boston Scientific and Medtronic have started to catch up with Johnson & Johnson in terms of ablation catheters. However, to truly defeat Johnson & Johnson, advanced three-dimensional mapping systems are still essential.Therefore, companies like Medtronic have started to acquire or self-develop their own 3D mapping systems. As one of the traditional three major players in electrophysiology, Boston Scientific is also a pioneer in the new era., which itself has its own three-dimensional mapping system OPAL HDx, but withCarto 3 still has some gaps, so it also needs to strengthen itself through mergers and acquisitions like Medtronic.CortexMapping SystemOptiMapUndoubtedly the best choice.OptiMapIs the first and only FDA-approved atrial fibrillation mapping system.
OptiMapIt is a mapping system based on Electrographic Flow (EGF).OptiMapComplete spatiotemporal reconstruction of atrial wavefront propagation can be achieved through EGF technology to identify active AF sources and estimate the consistency of observed wavefront patterns.
According to the previousCortexIntroduction, a previous clinical study showedOptiMapAble to improve the non-recurrence rate of atrial fibrillation by 51% after pulmonary vein electrical isolation (compared to only performing pulmonary vein electrical isolation without...OptiMapMapping）
Duke Rohlen is a serial entrepreneur and the founder of Ajax Health. The total value of his innovative companies that have been sold has reached $1.7 billion, including FoxHollow Technologies (acquired by Ev3 for $780 million, now part of Medtronic), CV Ingenuity (acquired by Covidien for $300 million), Spirox, Inc. (acquired by Entellus Medical for over $200 million), and EPIX Therapeutics (acquired by Medtronic for $350 million).Duke Rohlen UnitedHellman&Friedman（H&F）Acquiring Cordis for $1 billion, the goal is to completely rebuild Cordis and make it great again.Duke Rohlen’s arrival will bring a fresh perspective and new ideas to Cordis. Duke Rohlen is currently a member of the Cordis Board of Directors and the CEO of Cordis-X.
Duke Rohlen in EstablishmentCortexPreviously, another electrophysiology company, EPIX Therapeutics, was established. This company was later acquired by Medtronic for $350 million. It can be said thatDuke Rohlen is a veteran entrepreneur in the electrophysiology field, subsequentlyDUke Rohlen may also bring revolutionary electrophysiology products.
CortexIs a newly established innovative company, which isIn the development of an advanced, seamlessly integrated comprehensive platform for the diagnosis and treatment of atrial fibrillation. ItsThe goal is to achieve more precise and personalized treatment planning and implementation to optimize clinical outcomes and safety for patients with atrial fibrillation, while streamlining workflows and improving procedural efficiency. Its technology suite will include diagnostic and pulsed field ablation catheters, as well as an integrated mapping and navigation solution powered by Ablacon's innovative Electrographic Flow (EGF) mapping technology.
